Pharmicell Co., Ltd. is a South Korean biopharmaceutical company operating both chemical (API) and biologics (stem cell therapy) divisions, with CDMO services. The Chemical Business Unit in Ulsan (Onsan) manufactures oligonucleosides, pharmaceutical PEGs, and industrial advanced materials. The Bio division developed the world's first approved stem cell therapy (Hearticellgram AMI for cardiac repair) and provides CDMO services for advanced cell therapies with GMP facilities including Grade B/C clean rooms, virus testing labs, and microorganism testing labs. The company holds ISO 9001, ISO 14001 certifications and reported record revenue of 114 billion KRW in 2025. Pharmicell is expanding CDMO operations for regenerative medicine with capability to handle 7 cell types.
Stem cell therapy CDMO (world's first approved stem cell therapy Hearticellgram AMI), oligonucleotide synthesis, pharmaceutical PEG manufacturing, cell culture and GMP processing, quality control testing for advanced biopharmaceuticals
1 site worldwide
Involvement in 1 clinical trial
No reviews available yet.
No documents available.